Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.06
EPS est.
$-0.69
EPS surprise
+91.32%
1-day move
+33.86%
Insmed's earnings report showed a significant surprise in EPS, which likely contributed to the stock's strong 33.86% increase. Investors may be encouraged by the positive EPS surprise, even though revenue details were not provided. The lack of guidance and management commentary leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.06 | N/A | +91.32% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Insmed Incorporated is a biotechnology company focused on developing innovative therapies for patients with serious and rare diseases. Operating in the health care sector, Insmed's work is particularly relevant as the demand for specialized treatments continues to grow.
Last quarter
In Q1 2026, Insmed reported an EPS of -$0.76, which was better than the expected -$0.90, resulting in a positive surprise. However, the stock dropped significantly by 23.41% the following day, indicating market disappointment despite the earnings beat.
EPS beat streak
2Q
EPS beat rate
25%
Avg EPS surprise
-3.23%
Avg 1-day reaction
+2.89%
Overall, expectations are mixed as Insmed has a history of volatile earnings reactions. Investors are looking for any signs of improvement in profitability and revenue growth.
Bull case
If Insmed can show a significant reduction in losses or an unexpected increase in revenue, it could lead to a strong positive reaction from investors.
Bear case
Conversely, if the company reports worse-than-expected losses or fails to provide guidance on future growth, it could lead to further declines in stock price.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to previous estimates?
Given the company's recent history of earnings surprises, the EPS figure will be crucial in determining market sentiment.
Q2
What guidance does management provide for future revenue growth?
Investors will be closely watching for any forward-looking statements that could indicate the company's growth trajectory.
—
Est. EPS
$3.08
Est. Rev
$7.2B
Impl. Move
±4.0%
Why consensus could be wrong
The Street may underestimate Insmed's potential for a turnaround given recent operational improvements that are not reflected in current estimates.
Supporting evidence
The options market is pricing a 21.56% move, suggesting high uncertainty that could lead to a larger reaction than expected.
Insmed's recent EPS surprise of +15.84% indicates potential for better-than-expected performance.
Key risk
If the company reports an EPS loss below -$0.50, it could shift market sentiment significantly.
Pre-commit to what would confirm each case.
This quarter, the market is focused on whether Insmed can show signs of financial recovery or if it will continue to struggle.
Bull confirmed if
A reduction in EPS losses to below -$0.50 would signal improved operational efficiency.
Bear confirmed if
An EPS loss greater than -$1.00 would confirm ongoing challenges in profitability.
What the market is pricing for the move.
Implied Move
±21.56%
Historical Avg
±11.3%
The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.
Options are pricing ±21.6% while INSM has averaged ±11.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
92.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
105.05%
of float
Insider
0.51%
of float
Holders
970
institutions
Top Holders· as of Jun 2026
FMR, LLC
16,143,583 sh · $1.6B
7.39%
22.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Insmed beats expectations and raises guidance, history suggests the stock could see an average one-day move of around +16.33%.
In line / cautious
If results are in line with expectations, management's commentary will likely dictate a muted reaction, potentially leading to a small move.
Miss
Should the company miss expectations, history suggests a potential decline of around +1.98% on the following day.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
15,807,984 sh · $1.6B
7.24%
-5.2%
JPMORGAN CHASE & CO
10,428,170 sh · $1.1B
4.78%
-56.8%
Vanguard Portfolio Management LLC
10,407,962 sh · $1.1B
4.77%
0.3%
Vanguard Capital Management LLC
9,790,865 sh · $996.1M
4.48%
1.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jun 10, 2026 · disclosed Jul 7, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.